CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models

SIMPLE SUMMARY: The cyclin E/CDK2 complex may present a promising target axis for the treatment of triple-negative breast cancers (TNBC); however, therapeutically relevant doses of CDK2 inhibitors have been associated with toxicities. Here, we report that the suboptimal dosing of the CDK 2, 7 and 9...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Anthony, Chenoweth, Alicia M., Quist, Jelmar, Sow, Heng Sheng, Malaktou, Christina, Ferro, Riccardo, Hoffmann, Ricarda M., Osborn, Gabriel, Sachouli, Eirini, French, Elise, Marlow, Rebecca, Lacy, Katie E., Papa, Sophie, Grigoriadis, Anita, Karagiannis, Sophia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322647/
https://www.ncbi.nlm.nih.gov/pubmed/35884422
http://dx.doi.org/10.3390/cancers14143361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322647/
https://www.ncbi.nlm.nih.gov/pubmed/35884422
http://dx.doi.org/10.3390/cancers14143361

Ejemplares similares